A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 4, 2007, Pages 306-311

  Lilenbaum, Rogerio ^a   Rubin, Mark ^b   Samuel, Joyce ^c   Boros, Laszlo ^d   Chidiac, Tarek ^e   Seigel, Leonard ^f   Dowlati, Afshin ^g   Graham, Patricia ^h   Beaumont, Jennifer ⁱ   Du, Hongyan ⁱ  

^a Mount Sinai Cancer Center   (United States)

^b Florida Cancer Specialists and Research Institute   (United States)

^c Jr Hospital of Cook County   (United States)

^d Interlakes Oncology and Hematology PC   (United States)

^e Mid Ohio Oncology Group   (United States)

^f HOLY CROSS HOSPITAL   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h SARAH CANNON RESEARCH INSTITUTE   (United States)

ⁱ Research and Education   (United States)

Author keywords

Advanced non small cell lung cancer; Docetaxel; Elderly

Indexed keywords

DEXAMETHASONE; DOCETAXEL; TAXOID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; AGE; CANCER STAGING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MORTALITY; PATHOLOGY; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; SURVIVAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM STAGING; NEUTROPENIA; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 34247877762     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000263713.38826.8e     Document Type: Article

References (23)

1. Bunn PA. Chemotherapy for advanced non-small cell lung cancer: who, what, when, why? J Clin Oncol 2002;20:23s-33s.
2. Sandler B, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial E4599. Clin Oncol 2005;23:LBA4, abstract.
3. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
4. Lilenbaum R. Treatment of advanced non-small-cell lung cancer in special populations. Oncology (Williston Park). 2004;18:1321-1325.
5. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005;23:3125-3137.
6. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
7. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181.
8. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005;23:190-196.
9. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
10. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63.
11. Hainsworth JD, Burris 3rdHA Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168.
12. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996-2004.
13. Camps C, Massuti B, Jiménez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006;17:467-472.
14. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of secondline chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23:8389-8395.
15. Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II trial of weekly docetaxel in second-line therapy for non-small cell lung carcinoma. Cancer 2001;29:2158-2163.
16. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
17. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J Clin Epidemiol 2002;55:285-295.
18. Briasoulis E, Karavasilis V, Anastasopoulos D, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999;10:701-706.
19. Hainsworth JD, Burris HA 3rd, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000;89:328-33.
20. Hesketh PJ, Chansky K, Lau DH, Crowley J, Gandara DR. for the Southwest Oncology Group. Sequential vinorelbine (V) and docetaxel (D) in advanced nonsmall cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: a SWOG phase II trial (S0027). J Clin Oncol 2004;22:7056, abstract.
21. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study. J Clin Oncol 2005;23:6865-6872.
22. Hesketh PJ, Lilenbaum R, Chansky K, et al. Chemotherapy in patients > 80 with advanced non small cell lung cancer: combined results from SWOG 0027 and LUN 6. J Clin Oncol 2005;23:7147, abstract.
23. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (<70). Proc Am Soc Clin Oncol 2003;22:639, abstract 2571.